期刊文献+

非临床安全性评价中离乳前给药的幼龄动物分组设计 被引量:9

Design on grouping of juvenile animal dosed prior to weaning during non-clinical safety evaluation
原文传递
导出
摘要 依据儿童年龄的划分,幼龄动物非临床研究的初次给药可能会在离乳前。因此,给药设计是以窝为背景进行的。对于啮齿类动物生理和行为的变化,窝的影响最大,随着动物年龄的变化更是如此。幼龄动物非临床研究设计中也必须考虑到窝的影响。幼龄动物非临床研究中窝的构成主要有:1窝内设计。2窝间设计。3单只幼仔/性别/窝。4抚育设计。本文结合本实验室的经验针对各种分组设计的优缺点、关键点包括操作程序和孕鼠数量等展开论述。 Depending upon the pediatric age classification,juvenile toxicity studies often initiate dosing prior to weaning. Therefore,dosing must be performed in the litter setting. The litter is the largest contributor to physical and behavioral variability in rodents and actually becomes more so as animals age. Juvenile non-clinical research design must also consider the influence of the litter. There are several methods of litter composition:1 within litter design; 2 between litter design; 3 one pup per sex per litter design; 4 fostering design. In this paper,combined with the experience of our laboratory,the advantages and disadvantages of the experimental grouping,and key points including operating procedures and number of pregnant rats were discussed.
作者 周莉 孙祖越
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第21期2483-2488,共6页 Chinese Journal of New Drugs
基金 上海市实验动物创新行动计划项目(14140901302) 上海市男性生殖与泌尿疾病药物非临床评价专业技术服务平台(15DZ2290400)
关键词 幼龄动物 非临床安全性评价 窝内设计 窝间设计 交叉抚育设计 juvenile animal non-clinical safety evaluation within litter design between litter design fostering design
  • 相关文献

参考文献13

  • 1孙祖越,周莉,韩玲.儿科用药非临床安全性评价要则及中药评价的特殊性[J].中国药理学与毒理学杂志,2016,30(1):13-20. 被引量:41
  • 2MYERS DP,BOTTOMLEY AM,WILLOUGHBY CR. Juveniletoxicity studies: key issues in study design [J]. Reprod Toxicol,2005,20: 475 - 476.
  • 3Organization for Economic Cooperation and Development,Guide-line for Testing of Chemicals. No. 414,Teratogenicity[EB/OL]. ( 2001 ) . http:// www. oecd. org/ chemicalsafety/ testing/oecdguidelinesforthetestingofchemicals. htm.
  • 4TANIMURA T. Guidelines for developmental toxicity testing ofchemicals in Japan[J]. Neurobehav Toxicol Teratol,1985,7( 6) : 647 - 652.
  • 5FDA. Guidance for Industry and Other Stakeholders ToxicologicalPrinciples for the Safety Assessment of Food Ingredients[EB/OL]. ( 2000 - 07 ) . http:// www. fda. gov/ downloads/ Food/GuidanceRegulation/ UCM222779. pdf.
  • 6HOLSON RR,PEARCE B. Principles and pitfalls in the analysisof prenatal treatment effects in multiparous species [J]. Neuro-toxicol Teratol,1992,14( 3) : 221 - 228.
  • 7DE SCHAEPDRIJVER LM,BAILEY GP,COOGAN TP,et al.Juvenile animal toxicity assessments: decision strategies and stud-y design[M]. Pediatric Drug Development: Concepts and Appli-cations,2013: 201 - 221.
  • 8RUPPERT PH,DEAN KF,REITER LW. Comparative develop-mental toxicity of triethyltin using split-litter and whole-litter do-sing[J]. J Toxicol Environ Health,1983,12( 1) : 73 - 87.
  • 9PEARSON DE,TEICHER MH,SHAYWITZ BA,et al. Envi-ronmental influences on body weight and behavior in developingrats after neonatal 6-hydroxydopamine[J]. Science,1980,209( 4457) : 715 - 717.
  • 10BECK MJ,MACGINNIS G,PADGETT EL,et al. Nonclinical ju-venile toxicity testing[M]. Hood RD. Developmental and Repro-ductive Toxicology: A Practical Approach. 3rd ed. London: CRCPress,2012: 302 - 339.

二级参考文献34

  • 1Roberts R,Rodriguez W,Murphy D,Crescenzi T.Pediatric drug labeling:improving the safety and efficacy of pediatric therapies[J].JAMA,2003,290(7):905-911.
  • 2Department of Health and Human Services,FDA.Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and Biological products in pediatric patients-FDA.Final rule[J].Fed Regist,1998,63(231):66631-66672.
  • 3FDA.Best Pharmaceuticals for Children Act.Public Law,2002:107-109[EB/OL].(2011-01-10)[2015-12-18]http://www.fda.gov/regulatoryinformation/legislation/significantamendmenttothefdcact/ucm148011.htm.
  • 4Guideline ICH Harmonised Tripartite.Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2)[C/OL]//International Conference on Harmonisation of Echnical Requirements for Registration of Pharmaceuticals for Human Use,(2009-06-11)[2015-12-18]http://www.ich.org/fileadmin/Public_Web_Site/CH_Prod M3_R2_Guideline.pdf.
  • 5FDA.Center for Drug Evaluation and Research.Guidance for Industry:Nonclinical Safety Evaluation of Pediatric Drug Products[EB/OL].U.S.Department of Health and Human Services,Rockville,MD,(2006-02)[2015-12-18].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079247.pdf.
  • 6European Medicines Agency(EMA),Committee for Human Medicinal Products(CHMP).Guideline on the Need for Non-Clinical Testing in Juvenile Animals on Human Pharmaceuticals for Pediatric Indications[EB/OL].(2008-01)[2015-12-18].htp:/www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/C500003305.pdf.
  • 7CFDA.Technical Guidelines for Population Pharmacokinetic Studies of Chemical Medicine in Pediatrics(化学药物儿科人群药代动力学研究技术指导原则)[EB/OL].(2014-07-11)[2015-12-18].http://www.cde.org.cn/zdyz.do?method=large Page&id=201.
  • 8Center for Drug Evaluation of CFDA.Technical Guidelines for Population Drug Clinical Trials in Pediatrics(exposure draft)〔儿科人群药物临床试验技术指导原则(征求意见稿)〕[EB/OL].(2015-07)[2015-12-18].http://www.cde.org.cn/zdyz.do?method=large Page&id=22207)[2015-12-18].http://www.cde.org.cn/zdyz.do?method=large Page&id=222.
  • 9Leconte I,Bailey G,Davis BK,Hew KW,Kim J,Lima BS,et al.Value of juvenile animal studies[J].Birth Defects Res B Dev Reprod Toxicol,2011,92(4):292-303.
  • 10Beck MJ,Macginnis G,Padgett EL,Parker GA,Toot JD,Varsho JS.Nonclinical juvenile toxicity testing[M]//Hood RD Developmental and Reproductive Toxicology:A Practical Approach.3rd ed.London:CRC Press,2012.

共引文献49

同被引文献50

引证文献9

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部